Clinical trials: Hypersensitivity Reactions
Asthma
Study of MAP0010 in Asthmatic Children and Adolescents
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
- Trial name
- NCT00697801
- Testing
- MAP0010 low dose, MAP0010 high dose
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Allergan
Asthma, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
- Conditions
- Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00862641
- Testing
- Regadenoson
- Where
- 48 sites in United States
- Volunteers
- 1,009 people
- Sponsor
- Astellas Pharma Inc
Asthma, Healthy Subjects or Volunteers
A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers
The primary objective of this study is to evaluate the pharmacokinetics (PK) and tolerability of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers.
- Trial name
- NCT02085473
- Testing
- Tralokinumab 300 mg
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Conjunctivitis, Allergic
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01732757
- Testing
- Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Allergan
Asthma
Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma
This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres.
- Trial name
- NCT00509028
- Testing
- Budesonide, Conventional Asthma Therapy
- Where
- Japan
- Volunteers
- 241 people
- Sponsor
- AstraZeneca
Asthma
Randomized Prospective Trial of a Mobile Health Application for Asthma Self-Management
The investigators aim to study the clinical efficacy of a mobile health application, AsthmaCare, and it's impact on long term health outcomes for asthma.
- Trial name
- AsthmaCare (NCT02333630)
- Testing
- AsthmaCare mobile health application, Asthma education
- Volunteers
- 200 people
- Sponsor
- David Stukus
Asthma
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
The purpose of the study is to find out how well a long-acting beta agonist like salmeterol works in people with different forms of the same gene.
- Trial name
- SECS (NCT00595361)
- Testing
- salmeterol
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Asthma, Obesity
Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity
The purpose of this study is to examine whether there are higher levels of cysteinyl leukotrienes in obese subjects than in non-obese subjects.
- Trial name
- NCT01158573
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Asthma
Tezepelumab Home Use Study
This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or…
- Trial name
- PATH-HOME (NCT03968978)
- Testing
- Tezepelumab (APFS), Tezepelumab (AI)
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Conjunctivitis
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.
- Trial name
- NCT01174823
- Testing
- bepotastine besilate ophthalmic solution
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- Bausch & Lomb Incorporated
Chronic Urticaria
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyroperoxidase.
- Trial name
- NCT00481676
- Testing
- Omalizumab 75-375 mg, Loratadine, Clemastine
- Where
- 11 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Novartis
Seasonal Allergic Rhinitis
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)
- Trial name
- NCT00651118
- Testing
- azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
- Where
- 43 sites in United States
- Volunteers
- 832 people
- Sponsor
- Meda Pharmaceuticals
Seasonal Allergic Rhinitis
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
- Trial name
- NCT01915823
- Testing
- azelastine hydrochloride and fluticasone propionate, Dymista vehicle
- Where
- 31 sites in United States
- Volunteers
- 348 people
- Sponsor
- Meda Pharmaceuticals
Asthma
HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent…
- Trial name
- NCT01147848
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder
- Where
- 63 sites in United States, Argentina and 4 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Asthma, Aspirin-Induced
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD).
- Trial name
- NCT03028350
- Testing
- Ifetroban Oral Capsule
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Cumberland Pharmaceuticals
Seasonal Allergic Rhinitis
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
- Trial name
- NCT00883168
- Testing
- azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 1,791 people
- Sponsor
- Meda Pharmaceuticals
Sarcoidosis
Safety Study of Abatacept to Treat Refractory Sarcoidosis
The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.
- Trial name
- STAR (NCT00739960)
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Atopic Dermatitis, Eczema
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States.
- Trial name
- NCT01149759
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rockefeller University
Asthma, Healthy
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
- Trial name
- NCT00638989
- Testing
- CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.